# Dimi Kellari

> Dimi Kellari is the co-founder and CEO of Neion Bio, a New York biotech using genetically engineered chicken eggs as biological factories to produce complex biologics like monoclonal antibodies at a fraction of the usual cost. An MIT-trained aerospace engineer who previously built autonomous-vehicle infrastructure at Cavnue and worked at Alphabet's X moonshot factory and McKinsey, Kellari co-founded Neion in 2024 with biologist Dr. Sam Levin around a single question: why, in 2024, are we still making our most important medicines in hamster cells? In June 2026 the company closed an oversubscribed $23 million Series A led by Caffeinated Capital.

- **Role:** Co-Founder & CEO at Neion Bio
- **Organizations:** Neion Bio, Cavnue, Sidewalk Infrastructure Partners, X (Alphabet's Moonshot Factory), McKinsey & Company, SandboxAQ
- **Education:** Master of Science, Systems Engineering, Massachusetts Institute of Technology (MIT), Master of Engineering, Aerospace / Aeronautical & Astronautical Engineering, Imperial College London
- **Known for:** Co-founded Neion Bio (2024) and serves as CEO, Led Neion out of stealth in March 2026 with a multi-product biosimilar co-development and supply agreement with a major pharmaceutical company, Closed an oversubscribed $23 million Series A in June 2026

## Career timeline

- **pre-2020** — Senior Analyst at McKinsey & Company
- **2020** — Product & Strategy Manager at X, Alphabet's Moonshot Factory
- **2020** — Investor at Sidewalk Infrastructure Partners
- **2020-2024** — Ran product and engineering at Cavnue, building infrastructure for autonomous vehicles (~4 years)
- **2024** — Co-founded Neion Bio with Dr. Sam Levin
- **2026-03** — Neion Bio emerged from stealth with a multi-product biosimilar partnership and ~$11M in financing
- **2026-06** — Closed an oversubscribed $23M Series A led by Caffeinated Capital

## Achievements

- Co-founded Neion Bio (2024) and serves as CEO
- Led Neion out of stealth in March 2026 with a multi-product biosimilar co-development and supply agreement with a major pharmaceutical company
- Closed an oversubscribed $23 million Series A in June 2026
- Built and commercialized the Raptor platform, producing recombinant biologics inside chicken eggs
- Previously ran product and engineering at autonomous-vehicle infrastructure company Cavnue

## Latest updates

- **2026-06** — Neion Bio closed an oversubscribed $23M Series A led by Caffeinated Capital, with Digitalis Ventures, Ensemble VC, Trust Ventures, and follow-on from Haystack and Basis Set Ventures.
- **2026-03** — Neion Bio emerged from stealth with its Raptor platform and a multi-product biosimilar partnership with a major pharma company.

## Links

- Website: https://neionbio.com
- LinkedIn: https://www.linkedin.com/in/demetrioskellari/

---

Profile page: https://yespress.io/dimi-kellari
Published by YesPress — https://yespress.io
Last updated: 2026-07-20